Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2025	Sep. 30, 2024
Current assets:
Cash, cash equivalents and restricted cash	$ 226,548	$ 102,685
Accounts receivable	6,824	0
Available-for-sale securities, at fair value	692,818	578,276
Prepaid expenses	10,933	9,537
Other current assets	13,516	4,973
Total current assets	950,639	695,471
Property, plant and equipment, net	382,515	386,032
Intangible assets, net	6,861	8,562
Right-of-use assets	43,891	45,255
Other assets	1,389	4,482
Total Assets	1,385,295	1,139,802
Current liabilities:
Accounts payable	17,674	11,388
Accrued expenses	90,419	63,017
Accrued payroll and benefits	26,895	21,989
Lease liabilities	7,289	6,342
Deferred revenue	2,399	0
Credit facility	40,000	0
Other liabilities	10,811	432
Total current liabilities	195,487	103,168
Long-term liabilities:
Lease liabilities, net of current portion	104,112	111,027
Liability related to the sale of future royalties	367,397	341,361
Credit facility, net of current portion	214,883	393,183
Total long-term liabilities	686,392	845,571
Commitments and contingencies (Note 7)
Noncontrolling interest and stockholders' equity:
Common stock, $0.001 par value: Authorized 290,000 shares; issued and outstanding 135,702 and 124,376 shares at September 30, 2025 and 2024, respectively	231	217
Additional paid-in capital	2,139,725	1,806,000
Accumulated other comprehensive income	6,443	4,750
Accumulated deficit	(1,627,154)	(1,625,523)
Treasury stock; at cost; 2,661 and 0 shares of common stock at September 30, 2025 and 2024, respectively	(53,193)	0
Total Arrowhead Pharmaceuticals, Inc. stockholders' equity	466,052	185,444
Noncontrolling interest	37,364	5,619
Total noncontrolling interest and stockholders' equity	503,416	191,063
Total Liabilities, Noncontrolling Interest and Stockholders' Equity	1,385,295	1,139,802
Consolidated Entity Excluding Variable Interest Entities (VIE)
Current assets:
Cash, cash equivalents and restricted cash	88,706	76,208
Variable Interest Entity, Primary Beneficiary
Current assets:
Cash, cash equivalents and restricted cash	$ 137,842	$ 26,477